Cost-effectiveness research
Executive Summary
Merck/AARP "invitation only" conference on cost-effectiveness/outcomes research is set for Jan. 28. The stakeholders meeting, which will include the Agency for Healthcare Research & Quality as a key participant, will attempt to develop a consensus on standards for research. Wharton Health Care Systems Department Chairman Mark Pauly, MD, will moderate the meeting (1"The Pink Sheet" Nov. 10, 2003, p. 3). The Pharmaceutical Research & Manufacturers of America is expected to discuss a position on outcomes research during its next board meeting, Jan. 15...
You may also be interested in...
Outcomes Research Should Come After Approval, FDA’s McClellan Says
The appropriate timing for outcomes research is after a product is approved for commercial marketing, FDA Commissioner McClellan told a recent conference on outcomes research sponsored by Merck and AARP
PhRMA Adopts Outcomes Research Policy; Set For Cost-Effectiveness Debate
Government-supported health outcomes research must recognize the benefits of multiple treatment options, the Pharmaceutical Research & Manufacturers of America's principles on outcomes research say
Rx Cost-Effectiveness Beyond Medicare: Merck, AARP Plan Policy Meeting
Merck and AARP are working with the Agency for Healthcare Research & Quality to organize a "stakeholders" meeting to discuss standards for cost-effectiveness research